Business Context and Reporting Period
This Form 8-K is a current report filed by Calidi Biotherapeutics, Inc. (CLDI) on November 29, 2023. The filing addresses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the resignation of Mr. Alfonso Zulueta as a director of the Company and as a member of the audit committee, effective immediately on November 29, 2023.
Management Commentary and Risks
- Reason for Departure: The Board stated that Mr. Zulueta's resignation is for personal reasons.
- Disagreement Status: The filing explicitly confirms the resignation is not due to any disagreement with management or the Board regarding operations, policies, practices, or accounting policies.
- Outlook: No financial guidance or operational outlook is provided in this document.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors and the Audit Committee following Mr. Zulueta's immediate departure.
- Confirm if a replacement director has been appointed or if the Board intends to fill the vacancy.
- Review subsequent filings for any impact on the Company's audit oversight or governance structure.